ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2879

What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?

Regan Arendse1, Proton Rahman2, Denis Choquette3, J Antonio Avina-Zubieta4, Michel Zummer5, Milton F. Baker6, Jacqueline Stewart7, Isabelle Fortin8, Michelle Teo9, Emmanouil Rampakakis10, Eliofotisti Psaradellis11, Brendan Osborne12, Cathy Tkaczyk12, Karina Maslova13, Francois Nantel14 and Allen J Lehman13, 1University of Saskatchewan, Saskatoon, SK, Canada, 2Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, 3Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 4Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, 5Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, 6VIHA, Victoria, BC, Canada, 7Penticton Regional Hospital, Penticton, BC, Canada, 8Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 9Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, 10JSS Medical Research, St-Laurent, QC, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada, 13Janssen Inc., Toronto, ON, Canada, 1419 Green belt Dr, Janssen Inc., Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: anti-TNF therapy, AS, extraarticular manifestations, psoriatic arthritis and registry

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Dactylitis is one of the most commonly reported features in spondyloarthritis. It has been hypothesized that dactylitis is a functional enthesitis at the proximal interphalangeal joints, resulting in synovitis, tenosynovitis, bone and soft tissue oedema to the digit, and may simultaneously involve more than one digit.  

Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) with infliximab (IFX) or golimumab (GLM). Eligible people for this analysis included AS and PsA patients treated with IFX who were enrolled since 2005 or with GLM enrolled since 2010 who had available information on dactylitis. The McNemar (paired Chi-square) test was used to compare the presence of dactylitis over time.

Results: A total of 260 AS patients and 261 PsA patients were enrolled with a mean (SD) age at baseline of 46.1 (13.0) vs. 50.0 (12.0) years, disease duration of 6.4 (9.8) vs. 5.2 (6.8) years, and proportion of females 40.6% vs. 48.5%, respectively. Among patients with AS, dactylitis was reported in 6.2% and 2.2% of patients at baseline and 6 months, respectively; at 6 months of treatment 73.3% of AS patients with dactylitis at baseline had no dactylitis and 1.6% developed dactylitis (P=0.057).  For PsA higher proportions of dactylitis were observed with 30.7%, and 12.7%, respectively; at 6 months of treatment 69.0% of PsA patients with dactylitis at baseline had no dactylitis and 4.6% developed dactylitis (P<0.001). The distribution of dactylitis amongst digits is described in Table 1 with the highest prevalence observed for feet in AS and PsA patients.

Table 1: Distribution of Dactylitis amongst Digits in AS and PsA

 

AS       

PsA

Baseline

(N=260)

6 Months

(N=207)

Baseline

(N=261)

6 Months

(N=189)

HD1, %

1.9

0.5

4.2

2.6

HD2, %

3.1

1.0

9.2

5.3

HD3, %

3.1

2.4

8.0

5.3

HD4, %

1.5

1.0

8.0

2.6

HD5, %

1.5

1.4

5.4

3.2

FD1, %

2.7

0.5

8.0

1.1

FD2, %

3.8

0.5

12.6

3.7

FD3, %

2.3

0.5

11.1

3.2

FD4, %

2.3

1.0

14.9

5.3

FD5, %

1.5

0.0

10.0

1.6

HD=hand digit; FD=foot digit

Presence of dactylitis in hands or feet (any digit) was associated with significantly higher HAQ in AS and PsA (AS: ΔHAQ=1.36 (P≤0.001); PsA: ΔHAQ=0.64 (P≤0.001)). 

Conclusion: A considerable proportion of PsA patients had dactylitis at anti-TNF initiation in this Canadian real-world cohort. Although a lower proportion of patients had dactylitis among AS patients, the presence of dactylitis was associated with higher functional disability in both AS and PsA patients. Treatment with IFX or GLM for 6 months was associated with significant reduction in the prevalence of dactylitis.


Disclosure: R. Arendse, Janssen Inc., 5; P. Rahman, None; D. Choquette, Janssen Inc., 5,AbbVie, 5,Amgen, 5,Celgene, 5,BMS, 5,Pfizer Inc, 5; J. A. Avina-Zubieta, Janssen Inc., 5; M. Zummer, Janssen Inc, 5; M. F. Baker, Janssen Inc., 5; J. Stewart, Janssen Inc., 5; I. Fortin, Janssen Inc., 5; M. Teo, Janssen Inc., 5; E. Rampakakis, Bristol-Myers Squibb, 2; E. Psaradellis, JSS Medical Research, 3; B. Osborne, Janssen Inc., 3; C. Tkaczyk, Janssen Inc., 3; K. Maslova, Janssen Inc., 3; F. Nantel, Janssen Inc., 3; A. J. Lehman, Janssen Inc., 3.

To cite this abstract in AMA style:

Arendse R, Rahman P, Choquette D, Avina-Zubieta JA, Zummer M, Baker MF, Stewart J, Fortin I, Teo M, Rampakakis E, Psaradellis E, Osborne B, Tkaczyk C, Maslova K, Nantel F, Lehman AJ. What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/what-is-the-location-of-dactylitis-in-ankylosing-spondylitis-and-psoriatic-arthritis-patients-and-how-do-they-respond-to-anti-tnf-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-is-the-location-of-dactylitis-in-ankylosing-spondylitis-and-psoriatic-arthritis-patients-and-how-do-they-respond-to-anti-tnf-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology